Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Blood (2014) 124 (8): 1259–1265.

https://doi.org/10.1182/blood-2014-04-570044

Published: 2014

Journal Articles

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Paul M. Barr, MD, Margaret M. Briehl, PhD, Steven H Bernstein, MD, Jonathan W. Friedberg, MD, Andrea Baran, MS, Derick R. Peterson, PhD, Daniel Oscar Persky, MD, Carla Casulo, MD, Megan M. Herr, BS, Jamie Littleton, BSN, Erin Cebula, MPH, CCRP, Mark Schwartz, PhD, Soham D. Puvvada, MD, Robert T Dorr, PhD, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2013) 122 (21): 89.

https://doi.org/10.1182/blood.V122.21.89.89

Published: 2013

Journal Articles

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Heather L. Tardif, Song Yao, PhD, Bryan H. Goldman, MS, Catherine M. Spier, MD, Michael L. LeBlanc, PhD, Lisa M. Rimsza, MD, Daniel O. Persky, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Christine B. Ambrosone, PhD, Margaret M. Briehl, PhD

Blood (2010) 116 (21): 321.

https://doi.org/10.1182/blood.V116.21.321.321

Published: 2010

Journal Articles

Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.

Jolanta Skalska, PhD, Paul S Brookes, PhD, S. M Nadtochy, Shannon Hilchey, PhD, Craig T. Jordan, PhD, Monica L. Guzman, PhD, Sanjay Maggirwar, PhD, Margaret M Briehl, PhD, Steven H. Bernstein, MD

Blood (2009) 114 (22): 3774.

https://doi.org/10.1182/blood.V114.22.3774.3774

Published: 2009

Journal Articles

Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

Betty J. Glinsmann-Gibson, MS, Kelly A. Cycon, Shawn P. Murphy, Ph.D., Thomas P. Miller, M.D., Thomas M. Grogan, M.D., Margaret E. Tome, Ph.D., Margaret M. Briehl, Ph.D., Lisa M. Rimsza, MD

Blood (2006) 108 (11): 2040.

https://doi.org/10.1182/blood.V108.11.2040.2040

Published: 2006

Journal Articles

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Margaret E. Tome, David B. F. Johnson, Lisa M. Rimsza, Robin A. Roberts, Thomas M. Grogan, Thomas P. Miller, Larry W. Oberley, Margaret M. Briehl

Blood (2005) 106 (10): 3594–3601.

https://doi.org/10.1182/blood-2005-02-0487

Published: 2005

Journal Articles

Induction of mitochondrial changes in myeloma cells by imexon

Katerina Dvorakova, Caroline N. Waltmire, Claire M. Payne, Margaret E. Tome, Margaret M. Briehl, Robert T. Dorr

Blood (2001) 97 (11): 3544–3551.

https://doi.org/10.1182/blood.V97.11.3544

Published: 2001

NARROW

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.

Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Induction of mitochondrial changes in myeloma cells by imexon

Email alerts

ASH Publications

American Society of Hematology

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.

Induced Major Histocompatibility Class II (MHCII) Expression Does Not Alter Chemosensitivity, Radiosensitivity, Redox Potential, or Proliferation Rate in a CIITA-Transfected Diffuse Large B Cell Lymphoma (DLBCL) Cell Line.

A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis

Induction of mitochondrial changes in myeloma cells by imexon

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only